Talis Biomedical Corp Performance
The entity has a beta of 2.72, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Talis Biomedical will likely underperform. At this point, Talis Biomedical Corp has a negative expected return of -18.11%. Please make sure to validate Talis Biomedical's information ratio and skewness , to decide if Talis Biomedical Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Talis Biomedical Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 130.2 M |
Talis |
Talis Biomedical Relative Risk vs. Return Landscape
If you would invest 404.00 in Talis Biomedical Corp on August 24, 2024 and sell it today you would lose (404.00) from holding Talis Biomedical Corp or give up 100.0% of portfolio value over 90 days. Talis Biomedical Corp is currently does not generate positive expected returns and assumes 37.7395% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Talis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Talis Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Talis Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Talis Biomedical Corp, and traders can use it to determine the average amount a Talis Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.4798
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TLIS |
Estimated Market Risk
| 37.74 actual daily | 96 96% of assets are less volatile |
Expected Return
| -18.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.48 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Talis Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Talis Biomedical by adding Talis Biomedical to a well-diversified portfolio.
Talis Biomedical Fundamentals Growth
Talis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Talis Biomedical, and Talis Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Talis Pink Sheet performance.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X | ||||
| Revenue | 412 K | ||||
| EBITDA | (60.7 M) | ||||
| Cash And Equivalents | 165.37 M | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 19.67 M | ||||
| Debt To Equity | 0.19 % | ||||
| Book Value Per Share | 26.68 X | ||||
| Cash Flow From Operations | (53.24 M) | ||||
| Earnings Per Share | (28.02) X | ||||
| Total Asset | 98.34 M | ||||
| Retained Earnings | (539.96 M) | ||||
About Talis Biomedical Performance
Assessing Talis Biomedical's fundamental ratios provides investors with valuable insights into Talis Biomedical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Talis Biomedical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Talis Biomedical Corporation operates as a molecular diagnostic company. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. Talis Biomedical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.Things to note about Talis Biomedical Corp performance evaluation
Checking the ongoing alerts about Talis Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Talis Biomedical Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Talis Biomedical is not yet fully synchronised with the market data | |
| Talis Biomedical generated a negative expected return over the last 90 days | |
| Talis Biomedical has high historical volatility and very poor performance | |
| Talis Biomedical has some characteristics of a very speculative penny stock | |
| Talis Biomedical has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 412 K. Net Loss for the year was (62.01 M) with loss before overhead, payroll, taxes, and interest of (149.4 M). | |
| Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21. |
- Analyzing Talis Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Talis Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Talis Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Talis Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Talis Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Talis Biomedical's pink sheet. These opinions can provide insight into Talis Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |